<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170515033989N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-17</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of TENS on the severity of pain during medical abortion pain in the first trimester of pregnancy</public_title>
      <acronym></acronym>
      <scientific_title>The effect of TENS on the severity of pain during medical abortion in the first trimester of pregnancy in comparison with the control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59208</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization of block: There will be twelve blocks, each block containing 5 units. For randomization statistical software will be used and the result will provided to a person outside the research group. For each patient who meets the including, this person will be contacted and she will announce the group (control or case), Blinding description: In this study, TENS device is connected to both case and control groups, however, it is active in the case group and inactive in the control group. The person who fills in the questionnaire and records the outcomes, as well as the researcher who collects the information and the person who performs the analysis, are blind to the membership of participants.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Medical Abortion.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Using TENS and Ibuprofen to reduce pain in first trimester abortion candidates with misoprostol - Ibuprofen administration method: Ibuprofen Tab ( produced by Loghman Pharmaceuticals)  200 mg (in case of moderate pain) or 400 mg (in case of severe pain). TENS (HMB-1000 TENS, South Korea) : Four pads are placed two in the lower abdomen and two in the waist area, which is connected to the device with a wire. TENS is set at a frequency of 80 Hz with an intensity of 0 to 80 (according to the patient's wishes). Intervention 2: Control group: Use of unbound TENS (placebo) and ibuprofen to reduce pain in first trimester abortion candidates with misoprostol - Method of administration of ibuprofen tablet (produced by Loghman Pharmaceuticals) 200 mg (in case of moderate pain) or 400 mg (in case of  Severe pain). In this group, four TENS pads (HM-1000, made in South Korea) are placed two in the lower abdomen and two in the waist area, but the connection wire between the pad and the device is not connected.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is available on demand after being unidentifiable

When:
Up to six months from the publication of the results

To whom:
Researchers working in academic and scientific institutions

Conditions:
Mention a valid request from the applicant

Where to obtain:
Dr. Minoo Yaghmaei
m.yaghmaei@sbmu.ac.ir

How to obtain:
Must be emailed.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Minoo Yaghmaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hospital, Erabi street, Daneshjoo Blv, Shahriari sq, Evin</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717413</zip>
        <telephone>+98 21 2243 2560</telephone>
        <email>m.yaghmaei@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Minoo Yaghmaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hospital, Erabi street, Daneshjoo Blv, Shahriari sq, Evin</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985717413</zip>
        <telephone>+98 21 2243 2560</telephone>
        <email>m.yaghmaei@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Single pregnancy
Less than 13 weeks of pregnancy
Body mass index below 30 kg / m2
Candidate for termination of pregnancy with Misoprostol</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Sensitivity to Misoprostol and Ibuprofen
Drug addiction
History of chronic pain
History of using TENS</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Using TENS and Ibuprofen to reduce pain in first trimester abortion candidates with misoprostol - Ibuprofen administration method: Ibuprofen Tab ( produced by Loghman Pharmaceuticals)  200 mg (in case of moderate pain) or 400 mg (in case of severe pain). TENS (HMB-1000 TENS, South Korea) : Four pads are placed two in the lower abdomen and two in the waist area, which is connected to the device with a wire. TENS is set at a frequency of 80 Hz with an intensity of 0 to 80 (according to the patient's wishes).</i_keyword>
      <i_keyword>Control group: Use of unbound TENS (placebo) and ibuprofen to reduce pain in first trimester abortion candidates with misoprostol - Method of administration of ibuprofen tablet (produced by Loghman Pharmaceuticals) 200 mg (in case of moderate pain) or 400 mg (in case of  Severe pain). In this group, four TENS pads (HM-1000, made in South Korea) are placed two in the lower abdomen and two in the waist area, but the connection wire between the pad and the device is not connected.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ibuprofen intake. Timepoint: Once at the end of the abortion process. Method of measurement: Dosage consumed throughout the abortion process (mg).</prim_outcome>
      <prim_outcome>Pain. Timepoint: At the beginning of hospitalization - at the beginning of using TENS - at 2, 4, 6, 8 and 10 hours after TENS. Method of measurement: Numeral Visual scale (NVS).</prim_outcome>
      <prim_outcome>Satisfaction with the whole abortion process. Timepoint: Once the abortion process is completed. Method of measurement: Based on the question from the patient - bad - normal - good - excellent.</prim_outcome>
      <prim_outcome>Satisfaction with the analgesia process. Timepoint: Once the abortion process is completed. Method of measurement: Based on the question from the patient - bad - normal - good - excellent.</prim_outcome>
      <prim_outcome>Satisfaction with the use of the TENS device. Timepoint: Once the abortion process is completed. Method of measurement: Based on the question from the patient - bad - normal - good - excellent.</prim_outcome>
      <prim_outcome>Duration of use of TENS. Timepoint: Once the abortion process is completed. Method of measurement: Minute.</prim_outcome>
      <prim_outcome>Side effects. Timepoint: Once the abortion process is completed. Method of measurement: Question from the patient and examination and mention of the complication.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-18</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Taleghani Hospital, Arabi st., Daneshjoo Blv, Shahriari sq., Evin Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
